EnteroMedics Inc. Appoints Mark Bullivant as Vice President of Marketing
ST PAUL, MN -- (Marketwired) -- 04/09/14 -- EnteroMedics Inc.
(NASDAQ: ETRM), the developer of medical devices using neuroblocking
technology to treat obesity, metabolic diseases and other
gastrointestinal disorders, is pleased to announced that Mark
Bullivant has joined the organization as Vice President of Marketing.
He will report to Greg S. Lea, Senior Vice President, Chief Financial
Officer and Chief Operating Officer. Most recently, Mr. Bullivant was
Vice President of Global Marketing and International Sales at Terumo
Heart Inc., a subsidiary of Terumo Corporation where he was
responsible for developing strategic sales and marketing plans with
focus on expanding the business in US and International markets. Mark
brings 20 years of product management experience in both the medical
and surgical fields.
"I am pleased that Mark is joining us at such an important time for
the company as we begin to build our commercial infrastructure in
anticipation of possible FDA approval of VBLOC Therapy later this
year," said Greg S. Lea, Senior Vice President, Chief Financial
Officer and Chief Operating Officer. "His extensive marketing
experience, both in and outside of the United States, will be a huge
asset to the team as we translate our international experience into a
US commercialization effort."
About EnteroMedics Inc.
EnteroMedics is a medical device company focused on the development
and commercialization of its neuroscience based technology to treat
obesity and metabolic diseases. EnteroMedics' proprietary technology,
VBLOC(R) vagal blocking therapy, delivered by a pacemaker-like device
called the Maestro(R) Rechargeable System, is designed to
intermittently block the vagus nerves using high-frequency,
low-energy, electrical impulses. VBLOC allows people with obesity to
take a positive path towards weight loss, addressing the lifelong
challenge of obesity and its comorbidities without sacrificing
wellbeing or comfort. EnteroMedics' Maestro Rechargeable System has
received CE Mark and is listed on the Australian Register of
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements about
EnteroMedics Inc. Our actual results could differ materially from
those discussed due to known and unknown risks, uncertainties and
other factors including our limited history of operations; our losses
since inception and for the foreseeable future; our lack of
commercial regulatory approval for our Maestro(R) System for the
treatment of obesity in the United States or in any foreign market
other than Australia and the European Community; our preliminary
findings from our EMPOWER(TM) and ReCharge pivotal studies; our
ability to comply with the Nasdaq continued listing requirements; our
ability to commercialize our Maestro System; our dependence on third
parties to initiate and perform our clinical studies; the need to
obtain regulatory approval for any modifications to our Maestro
System; physician adoption of our Maestro System and VBLOC(R) vagal
blocking therapy; our ability to obtain third party coding, coverage
or payment levels; ongoing regulatory compliance; our dependence on
third party manufacturers and suppliers; the successful development
of our sales and marketing capabilities; our ability to raise
additional capital when needed; international commercialization and
operation; our ability to attract and retain management and other
personnel and to manage our growth effectively; potential product
liability claims; potential healthcare fraud and abuse claims;
healthcare legislative reform; and our ability to obtain and maintain
intellectual property protection for our technology and products.
These and additional risks and uncertainties are described more fully
in the Company's filings with the Securities and Exchange Commission,
particularly those factors identified as "risk factors" in the annual
report on Form 10-K filed March 27, 2014. We are providing this
information as of the date of this press release and do not undertake
any obligation to update any forward-looking statements contained in
this document as a result of new information, future events or
Caution - Investigational device. Limited by Federal (United States)
law to investigational use.
The implantation procedure and usage of the Maestro(R) System carry
some risks, such as the risks generally associated with laparoscopic
procedures and those related to treatment as described in the
ReCharge clinical study informed consent.
Greg S. Lea
Press spacebar to pause and continue. Press esc to stop.